Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD93+ and CD93- HSCs comparison [ATAC-Seq]

ABSTRACT: CD93+ and CD93- HSCs comparison [ATAC-Seq]

PROVIDER: PRJNA701027 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13669986_1.fastq.gz	Fastqsanger.gz
	SRR13669986_2.fastq.gz	Fastqsanger.gz
	SRR13669987_1.fastq.gz	Fastqsanger.gz
	SRR13669987_2.fastq.gz	Fastqsanger.gz
	SRR13669988_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

CD93+ and CD93- HSCs comparison [RNA-Seq]

Project description:CD93+ and CD93- HSCs comparison [RNA-Seq]

| PRJNA701026 | ENA

CD93+ and CD93- HSCs comparison

Project description:CD93+ and CD93- HSCs comparison

| PRJNA701025 | ENA

CD93+ and CD93- HSCs comparison [ATAC-Seq]

Project description:Hematopoietic stem cells (HSCs) are characterized by their ability to generate all blood cells while retaining their self-renewal capacity. While it is convenient to believe that HSCs represent a homogenous population, several evidences do not support this notion. Here we identified and characterized a HSC population that expressed CD93 on their membrane. This population showed strong molecular dHSC signature, combined with activation features. Thereby, suggesting that they represent an intermediate state between quiescent and active HSCs being more prone to respond upon alterations in the hematopoietic lineage

2021-08-02 | GSE166476 | GEO

CD93+ and CD93- HSCs comparison [RNA-Seq]

2021-08-02 | GSE166475 | GEO

ATAC-seq of HSCs.

Project description:ATAC-seq of HSCs.

| PRJNA834664 | ENA

ATAC-seq of control and Cyp26b1KO HSCs

Project description:ATAC-seq of control and Cyp26b1KO HSCs

| PRJEB41401 | ENA

ATAC-seq of LT-HSCs and MPPs

Project description:ATAC-seq of LT-HSCs and MPPs

| PRJEB41482 | ENA

Microarray data of human MLLr AML cells with or without CD93 expression

Project description:Leukemia stem cells (LSCs) share several crucial properties with hematopoietic stem cells (HSCs) including self-renewal, cell cycle quiescence, and expression of a CD34+CD38- immunophenotype, which complicates efforts to eradicate AML by therapeutically targeting LSCs without adversely affecting HSCs. Here we report that CD93, a C-type lectin transmembrane receptor, is preferentially expressed on the cell surface of LSCs compared with HSCs in the genetic subtype of AML with genomic rearrangements of the MLL gene. LSCs that selectively express CD93 are actively cycling, and highly enriched for xeno-engraftment potential, yet comprise a minor component of an otherwise quiescent CD34+CD38- compartment of human AML. Notably, CD93 is required for LSC function in MLL leukemogenesis, and is not simply a passive surface marker co-expressed on LSCs. Thus, CD93 selectively marks and essentially maintains LSCs, and identifies them as predominantly cycling, non-quiescent leukemia-initiating cells in MLL-rearranged AML.

2015-10-02 | GSE64776 | GEO

Comparison of transcriptional profiles of (1) intestinal ILC3s isolated from WT and IL-17D-deficient mice; (2) CD93+ILC3s and CD93-ILC3s from WT mice

Project description:IL-17D/CD93 axis was essential for ILC3s hemostasis. In order to further understand how IL-17D-CD93 axis regulate ILC3s function, we conducted RNA-seq analysis of ILC3s.

2021-05-20 | GSE165788 | GEO

CD93+ and CD93- HSCs comparison

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-08-02 | GSE166477 | GEO